Viking Therapeutics

Viking
Therapeutics
dan2023-12-14T22:48:39-05:00

Project Description

Initial Public Offering
Common Stock

$27,600,000

Sole Book-Runner
May 2015

Project Details

Categories:

IPO

© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

© Copyright 2015 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

Project Description

Project Details

Categories:

Site Info

Legal

Disclosures

Contact Info

Recent Posts

Stay In Touch

Contact Info

Project Description

Project Details

Categories:

Related Projects

Site Info

Legal

Disclosures

Contact Info

Recent Posts

Stay In Touch

Contact Info